News

One of these agreements is for the conjoint clinical development of aerosolized AAT for treating the indications of cystic fibrosis and bronchiectasis, in addition to Alpha-1 Antitrypsin Deficiency

agClinical, designed for the smaller life sciences companies, provides core trial management functionality and offers easy integration with multiple clinical applications, while agClinical NW helps large companies perform

Upon Mr. Moran’s retirement, Gary Siegel, currently vice president of finance, will assume the roles of principal accounting officer and principal financial officer. Mr. Siegel has served the

Omnitrope, a follow-on biologic, is approved for the long-term treatment of pediatric patients who have growth failure and long-term replacement therapy in adults with growth hormone deficiency. The

The product, developed by Debiopharm for the treatment of acute esophageal variceal bleeding (EVB), is currently under review for approval by the Canadian Health Authorities. In addition to

Now this agreement extended for four more years until March 2012, Astellas will continue to have access to MorphoSys’s proprietary antibody library HuCAL Gold at its research site

Separately, Essilor International’s subsidiary Essilor Canada has acquired a majority stake in Westlab Optical, a prescription laboratory located in Montreal. The partnership focuses primarily on developing the company’s

Bayer HealthCare will use Millipore’s UCOE (Ubiquitous Chromatin Opening Element) technology to manufacture biologic drugs. The license will enable Bayer to more efficiently manufacture recombinant proteins in mammalian

Zentase is a porcine-derived pancreatic enzyme replacement therapy which is being developed to treat pancreatic insufficiency. Gearoid Faherty, CEO of Eurand, said: “We understand that the typical FDA